The measured findings from sermorelin and modified GHRH analogues in older adults are narrower and more interesting than the marketing suggests. In a placebo-controlled trial of the modified analogue [Nle27]GHRH(1-29)-NH2 in age-advanced men and women, twelve-hour integrated nocturnal growth hormone rose significantly in both sexes, IGF-1 and IGFBP-3 increased within two weeks, and skin thickness improved in both — but lean body mass rose in men only, with no other change in body composition or bone mineral density (Khorram, Laughlin & Yen, J Clin Endocrinol Metab 1997).
What sermorelin actually does
Sermorelin is the first 29 amino acids of growth hormone-releasing hormone — the fragment that carries the biological activity. It is not growth hormone. It is the signal that tells your pituitary to release its own.
That one mechanical fact explains most of what follows. Because the pituitary remains in charge, release stays pulsatile and the feedback system that normally regulates it stays intact — somatostatin can still apply the brake. You get a nudge to a system rather than an override of it.
The consequences run in both directions. The upside is a safety profile shaped by your own physiology rather than by an externally imposed level. The limit is that a pituitary which cannot respond will not be made to, so sermorelin's ceiling is set by what your own gland can still do. That is the core of the sermorelin versus HGH comparison.
The measured sermorelin and GHRH analogue findings, in order of evidence
Growth hormone and IGF-1 rise. This is the best-supported effect and the one everything else depends on. In the trial of the modified analogue above, IGF-1 and its binding protein climbed within two weeks of starting. Studies of nightly GHRH in healthy elderly men found the releasing response was sustained across six weeks rather than fading, with no significant adverse effects (Vittone et al., Metabolism 1997) — the axis kept answering.
Skin thickness. Significantly increased in both men and women in the Khorram trial. A small, objectively measured, real finding.
Lean body mass. Increased in men only, and not in women in the modified GHRH analogue trial. That asymmetry is exactly the sort of detail promotional copy tends to lose.
Sleep. Growth hormone release is physiologically tied to slow-wave sleep, and improved sleep is often reported anecdotally. However, preliminary results from a placebo-controlled trial of sermorelin for age-related sleep problems did not show improvement; subjective sleep scores were slightly worse on treatment.
Body composition and bone density beyond the above. The trial found no other changes. Worth stating plainly, because the gap between "IGF-1 went up" and "your body recomposed" is where most overclaiming happens.
What sermorelin is not
It is not a substitute for growth hormone in someone whose pituitary cannot produce it. It is not a rapid intervention — the trial data measures effects over weeks to months, and the endocrine markers move well before anything subjective does. And it is not a weight-loss drug; the studied effects on body composition were modest, sex-specific and secondary.
If your goal is weight change, the metabolic support and fat loss category is a more honest place to start than a growth hormone secretagogue.
Who tends to be a candidate
Sermorelin is generally considered for adults whose own growth hormone output has declined with age and who have symptoms consistent with that — poor sleep quality, slow recovery, changes in body composition — rather than for anyone wanting a performance edge. Baseline labs, including IGF-1 and thyroid function, inform the decision, and untreated hypothyroidism should be corrected first because it blunts the response.
What rules people out matters as much: an active cancer diagnosis, pregnancy or breastfeeding, growth hormone deficiency stemming from an intracranial lesion, or known sensitivity to the formulation. Growth hormone and IGF-1 are growth-signalling pathways, and raising them deliberately is not a decision to make around an untreated malignancy.
The common side effects are mild and mostly local — injection-site reactions in roughly one patient in six, with almost everything else under 1%. We cover them in sermorelin side effects.
How this works at Promise
Promise offers sermorelin by prescription, after a licensed provider reviews your request. Through Promise, sermorelin is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Compounded medications are not reviewed by the FDA for safety, effectiveness, or quality. The research above includes studies of native GHRH(1–29) and a modified GHRH(1–29) analogue with an Nle27 substitution; it is not research on the compounded formulation offered here.
Every request goes to a licensed provider in Promise's prescriber network, who reviews your history and prescribes only when sermorelin is appropriate for you — or declines. Not everyone qualifies. That review, plus dispensing by a licensed U.S. compounding pharmacy, is the difference between a prescribed medication and a vial of unverified provenance.
The hormone and organ health hub covers the rest of the category, including CJC-1295/Ipamorelin and tesamorelin.
Setting expectations honestly
The strongest claim the evidence supports is that sermorelin raises your own growth-hormone release, with a mild side-effect profile. The IGF-1, skin-thickness and lean-mass findings come from a 16-week study of a modified GHRH analogue, [Nle27]GHRH(1-29)-NH2, in older men and women (Khorram et al., JCEM 1997); the six-week study of sermorelin itself in eleven older men found more nocturnal growth hormone but no change in IGF-1 or body composition (Vittone et al., Metabolism 1997). Everything beyond that is either under-studied or extrapolated.
That is a real result. It is not the transformation the category is often sold as, and knowing the difference before you start is the best predictor of being satisfied with what you get.
